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ABSTRACT 
Background and Aims: The adenoma detection rate (ADR) is a powerful measure of 
screening colonoscopy quality. Patients who undergo colonoscopy for evaluation of a positive 
fecal immunochemical test (FIT) have increased prevalence of colorectal neoplasia, but it is not 
known whether separate quality benchmarks are required. The aim of this study was to 
compare the conventional ADR to the ADR of colonoscopies performed for the evaluation of 
positive FIT, in asymptomatic average-risk patients. 
Methods: Patients ≥ 50 years old who underwent colonoscopy for the evaluation of a positive 
FIT between 1/1/2013 and 7/31/2014 at a tertiary Veterans Affairs Medical Center were 
identified. FIT performed for any indication other than average-risk screening were excluded. 
The comparison group included average-risk patients ≥ 50 years old undergoing screening 
colonoscopy during the same time frame. The 2 groups were compared for ADR, advanced 
neoplasm (adenoma ≥ 10 mm, tubulovillous, high-grade dysplasia, CRC, sessile serrated polyp 
[SSP] ≥ 10 mm), CRC, and SSP detection after propensity score adjustment using a logistic 
regression model adjusted for endoscopist. 
Results: There were 207 patients in the FIT group, and 601 in the screening colonoscopy 
comparison group. After propensity score adjustment, ADR (72.9% vs. 50.0%, p=0.003), 
number of adenomas per colonoscopy (3.3 ± 3.6 vs. 1.4 ± 2.3, p=0.033) and advanced 
neoplasm detection rate (32.4% vs. 11.0%, p<0.0001) were significantly higher in the FIT group. 
There were no significant differences in number of CRC, and the SSP detection rate.  
Conclusions: In this cohort of average-risk Veterans, the ADR of colonoscopies performed for  
evaluation of a positive FIT was higher than the ADR of screening colonoscopies. Patients with 
a positive FIT also had significantly more adenomas per colonoscopy and advanced neoplasms.  
These findings suggest that the quality of colonoscopies performed for a positive FIT is 
insufficiently assessed by the conventional ADR, and requires additional quality metrics. 
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INTRODUCTION 
 A fundamental goal of effective colonoscopy is colorectal cancer (CRC) prevention 
through the detection and removal of precancerous polyps. There is considerable evidence 
showing that the effectiveness of colonoscopy depends on the quality of the examination. The 
adenoma detection rate (ADR), defined as the proportion of screening colonoscopies where at 
least one adenoma is found, is currently the prime surrogate measure of colonoscopy 
performance quality 1, and is inversely associated with the risk of post-colonoscopy CRC2,3. The 
American Society for Gastrointestinal Endoscopy (ASGE)/American College of 
Gastroenterology (ACG) Task Force on Quality in Endoscopy has set minimum target detection 
rates in average-risk individuals of 30% for men and 20% for women 1. Although the ADR is a 
robust quality metric, unanswered questions remain about the optimal method for measurement. 
The conventional ADR calculation is based on screening colonoscopies, and minimum detection 
rates for colonoscopies performed for other indications, notably the evaluation of occult 
gastrointestinal bleeding, are not well defined.  
In its guideline, the ASGE/ACG Task Force states that further research is needed to 
determine whether (and within which parameters) the ADR can be used as a quality metric in 
screening programs that use fecal occult blood or immunochemistry testing to select patients for 
colonoscopy1. This issue is important because fecal immunochemical tests (FIT) have now 
emerged as the non-invasive CRC screening test of choice, and are the frontline CRC 
screening modality in several countries4. Patients with positive FIT have high prevalence rates 
of adenomas, advanced adenomas, and cancer5, adding to the rationale for development of 
separate ADR targets. In a recent guideline, the US Multi-Society Task Force on Colorectal 
Cancer proposed ADR benchmarks of 45% in men and 35% in women on colonoscopy 
examinations performed to evaluate a FIT-positive test (using a threshold of 20 µg 
hemoglobin/gm dry stool or less). However, this was a weak recommendation based on very 
low quality evidence, derived from series reporting the PPV for adenoma detection in FIT-based 
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screening programs6. In the Veterans Affairs healthcare system, colonoscopy and FIT are 
available concurrently as primary CRC screening options, allowing an opportunity to compare 
the yield of colonoscopy performed for both indications in the same population. Such data are a 
requisite step to develop ADR benchmarks for FIT-based programs. The aim of this study is to 
compare the conventional ADR to the ADR of colonoscopies performed for the evaluation of 
positive FIT, in asymptomatic average-risk Veterans. 
 
METHODS 
The study was approved by the Institutional Review Board at Indiana University-Purdue 
University at Indianapolis and by the Richard L. Roudebush VA Medical Center Research and 
Development Committee in Indianapolis, Indiana. Data sources included the Roudebush VA 
Medical Center GI endoscopy electronic database (ProVation Medical; Minneapolis, Minn), and 
the Veterans Affairs Vista Computerized Patient Record System (CPRS).   
 We conducted a retrospective study to compare the ADR for colonoscopies performed 
to evaluate a positive FIT, to the conventional ADR derived from screening colonoscopies. We 
included asymptomatic, average-risk Veterans ≥ 50 years old who had undergone outpatient 
colonoscopy between January 1, 2013 and July 31, 2014. In one group, the colonoscopy was 
done for CRC screening and in the other group, the colonoscopy was done for evaluation of a 
positive FIT, initially performed for CRC screening. We excluded patients with overt 
gastrointestinal bleeding, any indication other than screening (such as iron deficiency anemia, 
diarrhea, etc.), a personal history of CRC or inflammatory bowel disease, a significant family 
history of CRC (first degree relative ≤ 60 years old or multiple relatives with CRC), and those 
who had undergone colonoscopy for any indication in the preceding 5 years. The FIT in use at 
the Roudebush VAMC is the qualitative Polymedco (Cortland, NY) FIT, with cutoff set at 20 µg 
hemoglobin/gm dry stool. Of the total 435 patients who had a positive FIT during the study time 
frame, 207 met inclusion criteria. We randomly selected 601 average-risk patients 
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(approximating a 3:1 ratio) who had undergone screening colonoscopy during the same time 
frame, using the same eligibility criteria as for the positive FIT group.  
Data collection and definitions  
For each eligible procedure, we collected data regarding patient demographics and 
physical characteristics (including age, sex, race, weight, height), cigarette smoking, alcohol 
use, Charlson Comorbidity Score7, medication use (including calcium, NSAIDs and statins), 
sedation type and dose, bowel preparation quality (based on the Aronchick scale), trainee (GI 
fellow) participation, cecal intubation, withdrawal time, and resected polyp characteristics 
(including location, size in millimeters, morphology, and histology). The attending physician for 
each procedure was also recorded. Cecal intubation was defined as explicit documentation in 
the report that the appendix, cecal landmarks, and ileocecal valve were visualized and 
photographed. Advanced neoplasms included advanced adenomas (≥1 cm, villous histology, 
and high-grade dysplasia), sessile serrated polyps (SSP) ≥ 1cm, and cancer.  
Based on these polyp data, the following measurements were derived: ADR (proportion 
of colonoscopies with at least one adenoma, including advanced neoplasms), number of 
adenomas per colonoscopy (APC), advanced neoplasm detection rate (proportion of 
colonoscopies with at least one advanced neoplasm), and SSP detection rate (proportion of 
colonoscopies with at least one SSP).  
Statistical Analysis 
 Patient and procedure characteristics were summarized for the FIT and screening 
colonoscopy groups. Counts (percentages) were presented for categorical variables and mean 
± standard deviation (SD) for continuous variables. Categorical characteristics were compared 
with chi-square tests. A Mantel-Haenszel chi-square test was used to compare ADR between 
the 2 groups. Two-sample t tests were used to compare continuous variables.  
Given the retrospective nature of the study design, and potential for selection bias and 
confounding, we used propensity score analysis. This method approximates randomized 
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controlled trial situations, to allow comparison of outcomes between intervention groups8. 
Propensity scores were calculated using a logistic regression model adjusted for each 
endoscopist, to predict group membership from the set of characteristics. Variables were 
calculated for each group and compared by outcome for each of 5 strata. The variables were 
BMI, age, Withdrawal Time (min), Total Time (min), Time of Assessment, attending, gender, 
race, Current Smoker, on Statin, on NSAID, on Calcium, Charlson Comorbidity Index, Fellow 
(trainee), Prep Quality, and cecal intubation. Outcomes included ADR, adenoma per 
colonoscopy, advanced neoplasm detection rate, CRC, and SSP detection rate.   
Finally, we performed an exploratory analysis to calculate ADR benchmarks for FIT-
positive colonoscopies, using the methodology described by Hilsden et al 9. This was done 
using data from endoscopists with at least 5 colonoscopies in each group, and linear regression 
and calculation of Pearson’s correlation coefficient using ADR- FIT as the outcome and ADR-
screening colonoscopy as the predictor. 
The study was sufficiently powered (>80%) to detect the ADR differences observed 
between the two groups. However the number of endoscopists with at least 5 colonoscopies in 
each group was small, so only large correlations between the ADRs in the FIT-positive and 
screening colonoscopy groups would be detected as statistically significant. 
 
RESULTS 
A total of 207 patients were included in the FIT group, and 601 in the screening 
colonoscopy comparison group. The procedures were performed by a total of 23 endoscopists. 
There were no significant differences between the groups with regards to age, race, cigarette 
smoking, bowel preparation quality, trainee participation, and NSAID use. There were significant 
differences in sex, body mass index, Charlson comorbidity score, withdrawal time, and calcium 
supplementation (Table 1).  
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After propensity score adjustment, the ADR of the FIT group was significantly higher 
than the ADR of the screening colonoscopy group (72.9% vs. 50.0%, p=0.003). The APC (3.3 ± 
3.6 vs. 1.4 ± 2.3, p=0.033) and advanced neoplasm detection rate (32.4% vs. 11.0%, p<0.0001) 
were significantly higher in the FIT group. The number of CRC and SSP detection rate were not 
significantly different (Table 2).  
The ADRs and APCs of the 7 endoscopists who had performed at least 5 colonoscopies 
in each group are presented in Table 3. The exploratory analysis to calculate ADR benchmarks 
for FIT-positive colonoscopies could not be completed due to weak correlation between ADRs in 
the FIT-positive and screening colonoscopy groups (r=0.16).  
 
DISCUSSION 
 In this cohort of average-risk Veterans, the ADR of colonoscopies performed for 
evaluation of a positive FIT was significantly higher than the conventional screening 
colonoscopy ADR. In addition, patients with a positive FIT had significantly more adenomas per 
colonoscopy and advanced neoplasms. In the FIT-colonoscopy group, the overall ADR was 
about 1.5 times higher, the APC for the endoscopists with the highest procedure volume were 2-
3 fold higher, and the proportion of colonoscopies with at least one advanced neoplasm was 3 
times higher than in the screening colonoscopy group. The ADR increase in the FIT-positive 
group was notable, given the high ADR in the comparison screening colonoscopy group (50%). 
These findings justify separate quality benchmarks, and suggest that the ADR target  of 45% for 
men proposed by the ACG/ASGE Quality Task Force may in fact be an underestimate. Perhaps 
more importantly, the ADR alone may be insufficient to completely evaluate the quality for FIT-
colonoscopy, given the significant increment in total adenoma and advanced neoplasia 
detection.    
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 Previous studies 10-12 have shown that the APC is less corruptible and is a more 
comprehensive measure of colonoscopy quality than the conventional ADR. The ADR may 
mask information about overall adenoma burden, and endoscopists with seemingly similar 
ADRs may vary significantly with regards to total adenoma detection. The APC overcomes the 
“one and done” phenomenon10, where an endoscopist could meet benchmark ADR targets by 
finding and removing one adenoma, but conduct a low quality examination subsequently. 
Minimum APC targets for screening colonoscopy have been proposed13, but have not yet been 
guideline-endorsed. There are several reasons for this: (1) the APC metric is more cumbersome 
to measure than the conventional ADR, which could represent a significant barrier for uptake, 
(2) APC measurement may require placing resected adenomas into separate specimen bottles, 
which could increase costs, and (3) there are no data associating the APC with the risk of post-
colonoscopy CRC as there are for the conventional ADR2,3. This reasoning may need to be 
reconsidered in the case of colonoscopy for positive FIT. In our study, the APCs for FIT-
colonoscopies (range 2.5 to 4.6) were 2-3 fold higher than for screening colonoscopies 
performed by the same group of endoscopists (range 0.8-2.0), an incremental yield which would 
have been overlooked by measurement of the ADR alone.  
 The advanced neoplasia detection rate has also been proposed as a complementary 
quality metric14, because advanced adenomas have a higher risk of progressing to CRC, and 
because the high ADRs reported in the recent literature may be inflated by increased detection 
of less clinically relevant small and diminutive adenomas. However, measurement is more 
cumbersome and challenging than the conventional ADR, due to concerns about variability in 
polyp size estimation among endoscopists, and variability in interpretation of the presence of 
villous elements and grade of dysplasia among pathologists. Our study revealed a 3-fold 
increase in advanced neoplasia detection rates in FIT-colonoscopy compared to screening 
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colonoscopy, which also challenges the notion that the conventional ADR is sufficient to capture 
colonoscopy quality in FIT-based screening programs. 
One of our study’s strengths is the use of propensity score analyses. Patients referred 
for CRC screening using colonoscopy or FIT may differ in significant ways; for example, some 
clinicians may prefer the non-invasive FIT in older frail patients, and/or be more likely to 
recommend colonoscopy for younger and healthier patients. Propensity score analysis reduces 
the confounding and biases inherent to the retrospective design and lack of baseline 
randomization8. An important consideration is whether there is residual bias due to endoscopists 
conducting a more careful examination in FIT-positive patients, due to heightened suspicion of 
the presence of colorectal neoplasia. However, procedure and withdrawal time were included in 
the propensity score matching, and the withdrawal times for colonoscopies in which no polyps 
were found were not significantly different between the 2 groups.   
 Our study has several limitations. First, it was conducted at a single tertiary VA medical 
center, with a predominantly male population. Studies conducted in different settings and 
populations are required to assess the generalizability of our findings. Second, the overall 
sample size was relatively small, and limited by the number of positive screening FIT-
colonoscopies which were performed in average-risk patients during the study time frame. This 
resulted in small numbers of procedures per endoscopist, which likely contributed to the weak 
correlation between ADRs in the FIT-positive and screening colonoscopy groups and precluded 
the determination of FIT-colonoscopy ADR benchmarks as described by Hilsden et al.9. Third, 
we could not compare the FIT-positive group to patients who had undergone colonoscopy and 
had known negative FIT; in other words, the FIT status of the screening colonoscopy patients 
was unknown. However, the main comparison had to be against primary screening colonoscopy 
(without prior FIT), because this is how the conventional ADR is defined and measured. In 
addition, at our Medical Center, the two primary CRC screening options are either FIT or 
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colonoscopy, and average-risk patients who have a negative FIT are not referred to screening 
colonoscopy. Hence, addressing this issue requires a prospective study specifically designed 
with a FIT-negative colonoscopy group, which was beyond the scope of our work. 
Additional considerations pertain to the fact that the FIT used at our facility is qualitative and 
set at 20 µg/g; hence the findings may be most applicable to settings using the same 
parameters. It is known that the performance characteristics of FIT depend on the brand, 
whether it is quantitative of qualitative, and on the positivity threshold of the latter15. These 
considerations have been elegantly reviewed elsewhere5. In general, quantitative FIT may 
be better due to automation of the interpretation process and the ability to adjust the 
positivity threshold. In addition, a lower cutoff is associated with increased sensitivity for 
colorectal cancer (CRC). However, in the United States, the Food and Drug Administration 
requires the use of qualitative FIT, and the 20 µg/g threshold is commonly chosen to 
balance increased neoplasia detection with colonoscopy availability. With these 
considerations, the US Multi-Society Task Force in fact suggests a cutoff of ≤ 20 µg/g. Thus 
our approach, based on a widely used qualitative FIT with a lower (but pragmatic) cutoff, is 
in agreement with FDA guidance and guideline recommendations, while being applicable 
and relevant to many practices which use FIT for average-risk CRC screening. 
Another consideration is that adenoma yield would be expected to be increased for FIT-
positive colonoscopies, raising the question whether the increased ADR reflects the quality 
of the FIT, rather than colonoscopy. In reality, the effect of a FIT-based screening strategy 
depends on several factors, including the performance characteristics of the FIT itself, the 
quality of the underlying program including administration of the test, completion rates, 
processing, appropriate colonoscopic follow-up, and critically, the quality of the colonoscopy 
which is performed to evaluate the patient with a positive test. The US Multi-Society Task 
Force5 has in fact suggested quality metrics for each of these measures, in particular 
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colonoscopy quality for which ADR targets of 45% in men and 35% in women were 
suggested (if the FIT cutoff is ≤ 20 µg/g). In our study, all of the aforementioned factors are 
controlled for, given that the FIT used is qualitative and set at the appropriate threshold, and 
its use as part of a well-established screening program with high-quality processes for test 
administration and follow-up. The remaining unaddressed issue was whether the ADR and 
other quality metrics differed significantly for FIT-positive colonoscopies, compared to the 
conventional screening ADR; this was the primary aim of our work. 
 In conclusion, in a group of average-risk Veterans, the ADR of colonoscopies performed 
for evaluation of a positive FIT was higher than the ADR of screening colonoscopies. Patients 
with a positive FIT also had significantly more adenomas per colonoscopy and advanced 
neoplasms. Our findings suggest that the quality of colonoscopies performed for a positive FIT 
is insufficiently assessed by the conventional ADR, and requires concomitant measurement of 
the total number of adenomas per colonoscopy and advanced neoplasia detection rates. 
Additional studies in different settings are required to validate and determine the generalizability 
of our findings. 
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